Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Institut Pasteur
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 4, 2022
Distillery Therapeutics
Blocking thiamine metabolism for Pseudomonas aeruginosa infection
BioCentury | May 31, 2022
Product Development
WHO mobilizing monkeypox research strategy
Meeting to discuss designs for trials of therapies, vaccines
BioCentury | May 6, 2022
Discovery & Translation
Sanofi and ModeX’s Epstein-Barr vaccine; plus San Raffaele, Walden and more
BioCentury’s roundup of translational news
BioCentury | Mar 1, 2022
Deals
Feb. 28 Quick Takes: Heidelberg shares jump as Huadong takes stake
Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Dec 3, 2021
Distillery Therapeutics
A measles-vectored COVID-19 vaccine expressing the full-length spike protein
BioCentury | Jul 2, 2021
Distillery Therapeutics
A single-shot, measles-vectored vaccine for Lassa virus
DISEASE CATEGORY: Infectious disease
INDICATION: Viral hemorrhagic fever Vaccination with a measles virus vector expressing Lassa virus glycoprotein and nucleoprotein could prevent Lassa virus
INDICATION: Viral hemorrhagic fever Vaccination with a measles virus vector expressing Lassa virus glycoprotein and nucleoprotein could prevent Lassa virus
BioCentury | May 8, 2021
Targets & Mechanisms
Long COVID’s big tent needs to get more precise
Breaking the disease into subtypes will be important for getting more companies into the space
Items per page:
1 - 10 of 130